CVKD
Cadrenal Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-1.58 EPS
Last earnings -2.4% on 2026-05-07
$3.60
▲ +19.21%$3.60▼ -64.98%
over 1Y
L $2.86EODHDH $14.20
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+19.2%
1W+25.9%
1M-17.2%
3M-23.4%
YTD-50.9%
1Y-65.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.58x).
Return on equity -483.3% · latest
Cadrenal Therapeutics, Inc. shows limited reported revenue, and -483.3% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.58x).
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$2.70M | -$7.63M | -$11.0M | -$13.5M |
| Net income | -$6.71M | -$8.36M | -$10.7M | -$13.2M |
| Diluted EPS | -$0.85 | -$9.29 | -$8.73 | -$6.64 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$7.67M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-119.5%
FCF yield-113.8%
Quality & risk
ROIC (est.)-318.8%
Free cash flow-$12.6M
Total debt$597K
Net cash$3.41M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+33.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Material agreement2026-07-01
- 8-K Officer / director change2026-06-29
- 8-K Reg FD disclosure2026-06-18
- 8-K Officer / director change2026-06-03
- 8-K Earnings results2026-05-07
- 10-Q Quarterly report2026-05-07
- 8-K Reg FD disclosure2026-04-30
- S-3 Shelf registration (potential raise)2026-04-21
- 10-K Annual report2026-03-31
Recent filings
all on EDGAR ↗4Period ending 2026-06-292026-07-01open ↗8-KPeriod ending 2026-06-302026-07-01open ↗8-KPeriod ending 2026-06-252026-06-29open ↗4Period ending 2026-06-252026-06-26open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-162026-06-18open ↗8-KPeriod ending 2026-06-182026-06-18open ↗4Period ending 2026-06-112026-06-15open ↗144Filing2026-06-15open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-032026-06-05open ↗8-KPeriod ending 2026-05-282026-06-03open ↗
Frequently asked
- Is Cadrenal Therapeutics, Inc. (CVKD) a buy?
- CVKD currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.58x).
- What is Cadrenal Therapeutics, Inc.'s quality score?
- CVKD scores 37.019974858964915/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001937993, latest 10-Q filed 2026-05-07) · EODHD · as of 7/3/2026, 11:38:07 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.